SCHLIEREN, Switzerland, March 24, 2020 /PRNewswire/ -- InSphero AG, the pioneer of 3D cell-based assay technology, today announced that it will offer free safety testing for exploratory COVID-19 ...

InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, today announced the launch of 3D InSight™ Monkey Liver Microtissues, ...

Monthly contract screening service simplifies long-term, repeat-dose testing of drugs in 3D human liver microtissues for global pharmaceutical market. InSphero AG, the leading supplier of easy-to-use ...

3D cell cultures are no longer a futuristic idea. They’re already reshaping how we study diseases like cancer, offering more realistic models of how cells behave in the body. But despite their ...

SCHLIEREN, Switzerland, Nov. 4, 2019 /PRNewswire/ -- InSphero AG today announced the company received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held ...

SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero has selected InSphero's 3D InSight™ Human Liver Disease Platform to ...

SCHLIEREN, Switzerland--(BUSINESS WIRE)--InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company is making their proprietary, patented 96- and 384-microwell plates ...

InSphero 3D InSight™ Human Liver Microtissues were identified as a more sensitive, highly specific in vitro model for predicting drug induced liver injury (DILI) and investigating mechanisms of drug ...